On May 21, 2024 Aktis Oncology, a biotechnology company discovering and developing novel targeted radiopharmaceuticals to treat a broad range of solid tumors, reported a multi-target discovery collaboration agreement with Eli Lilly and Company to generate anticancer radiopharmaceuticals using Aktis Oncology’s novel miniprotein technology platform (Press release, Aktis Oncology, MAY 21, 2024, View Source [SID1234643506]). The collaboration draws on Aktis’ proprietary radiopharmaceutical platform together with Lilly’s expertise in oncology drug development and commercialization, with the goal of developing first-in-class and differentiated therapeutics for a range of solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our strategic collaboration with Lilly leverages Aktis’ unique miniprotein radiopharmaceutical platform capabilities to address novel targets, while delivering a safe and effective clinical profile," said Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology. "We are pleased to partner with Lilly in efforts to increase the number of patients that can derive meaningful clinical benefit from targeted radiopharmaceuticals."

Under the terms of the agreement, Aktis will receive a $60 million upfront cash payment for the collaboration in addition to an equity investment in Aktis by Lilly. In addition, Aktis will be eligible to receive up to an additional $1.1 billion in potential preclinical, clinical, regulatory and commercial milestones, as well as tiered royalties.

In exchange, Lilly will receive worldwide rights to develop radiopharmaceutical therapeutic and diagnostic products discovered by Aktis on a defined set of targets selected by Lilly.

"This collaboration with Aktis Oncology builds upon our growing radiopharmaceutical capabilities and provides access to an exciting and innovative technology for creating important and differentiated radiopharmaceuticals. We look forward to collaborating with Aktis and utilizing this emerging modality to bring forward meaningful new therapies for people with cancer," said Jacob Van Naarden, President, Lilly Oncology.

On May 21, 2024 Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated T cell immunotherapies for solid tumors and BioNTech SE (Nasdaq: BNTX, "BioNTech") reported that their collaboration to advance T cell receptor (TCR) immunotherapies against cancer will extend beyond the initial three-year term outlined at the signing of the agreement in February 2022 (Press release, MediGene, MAY 21, 2024, https://www.pressetext.com/news/20240521012 [SID1234643505]). This extension will enable ongoing and future work required to potentially generate novel TCRs directed against multiple newly nominated antigen targets that could further expand the BioNTech warehouse of TCR candidates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased about the extension of our partnership with BioNTech aiming at the development of highly differentiated TCR-based therapies for patients suffering from solid tumors. The collaboration solidifies our position as a leader in the field of TCR generation while we continue to deliver very promising TCR candidates," said Dr. Selwyn Ho, Chief Executive Officer at Medigene. "The ongoing work between our scientific teams reflects the strength of our partnership in the fight against cancer, and we look forward to making further progress in making a difference in the lives of cancer patients."

In February 2022, Medigene and BioNTech entered into a global multi-target collaboration to discover and develop T cell receptor immunotherapies against multiple cancer targets including PRAME (PReferentially expressed Antigen in MElanoma). The agreement also included non-exclusive licenses to some of the proprietary technologies contained in Medigene’s End-to-End Platform including its PD1-41BB costimulatory switch protein.

On May 21, 2024 NuCana plc (Nasdaq: NCNA) reported that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO (Free ASCO Whitepaper) & EHA (Free EHA Whitepaper) (Press release, Nucana BioPharmaceuticals, MAY 21, 2024, View Source [SID1234643500]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: TD Cowen’s 5th Annual Oncology Innovation Summit
Date: Tuesday, May 28, 2024
Time: 8:30 AM EDT
Location: Virtual

The presentation will be webcast live and available for replay under "Events & Presentations" in the Investors section of the Company’s website at www.nucana.com.

On May 21, 2024 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, reported the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer (CSO) and Executive Committee member, effective June 3, 2024 (Press release, Valneva, MAY 21, 2024, View Source [SID1234643499]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Valneva decided to complement its Executive Team with an accomplished R&D leader to oversee the further evolution of the Company´s R&D portfolio. Specifically, Dr. Schuitemaker will focus on accelerating Valneva’s pre-clinical and translational R&D activities in support of the Company’s strategic ambition to provide first-, best- or only-in-class vaccine solutions.

Dr. Schuitemaker brings more than two decades of experience in vaccine discovery and development. She formerly served as Global Head of Viral Vaccine Discovery and Translational Medicine at Johnson & Johnson (J&J), with responsibility for the strategy and execution of vaccine programs on COVID-19, HIV, RSV, Ebola, and multiple other viral disease targets for almost 14 years. Prior to J&J, she worked at Sanquin, The Netherlands’ Blood Supply Foundation, and at Amsterdam University Medical Center, where she conducted research on the pathogenesis of HIV. She has a unique and solid scientific background, which is notably reflected in more than 350 scientific publications.

Thomas Lingelbach, Chief Executive Officer of Valneva, said, "Hanneke’s addition to our team represents an important step in further strengthening Valneva’s strategic leadership, especially as we continue to build our R&D portfolio beyond our advanced clinical programs against Lyme disease and the chikungunya virus. Innovation is a foundation of Valneva’s culture and strategy, and we are confident that her expertise and vision will be key in this regard."

Dr. Schuitemaker, newly appointed Chief Scientific Officer of Valneva, added, "I am extremely excited to join the fantastic team at Valneva to help strengthen the pipeline and contribute to the design and development of novel vaccines against infectious diseases. Valneva has already accomplished a great deal, having brought three vaccines from early R&D to approval1, including the world’s first licensed chikungunya vaccine2, and I can’t wait to join the organization."

On May 21, 2024 Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, reported that management will participate in the following upcoming investor conferences (Press release, Tempest Therapeutics, MAY 21, 2024, View Source [SID1234643498]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen’s 5th Annual Oncology Innovation Summit – Fireside chat on Wednesday, May 29, 2024 at 2:00 p.m. ET

Jefferies Global Healthcare Conference – Presentation on Wednesday, June 5, 2024 at 4:00 p.m. ET
To access the live or archived recording of the discussions, please visit the investor section of the Tempest website at View Source